Decreasing Opioid Use Postpartum: A Quality Improvement Initiative.

OBJECTIVE: To estimate the effects of an inpatient initiative to decrease opioid use among women admitted to labor and delivery. METHODS: We created a multimodal pain power plan with standard therapeutic postpartum activity goals rather than pain goals, tiered order sets with scheduled administration of nonsteroidal antiinflammatory drugs (NSAIDs), and embedded changes into the electronic health record. Before the multimodal pain power plan launch, pain was assessed on a 10-point scale; women received NSAIDs for pain levels of 3 or less and opioids for pain levels higher than 3. For this analysis, we included women who delivered at 5 hospitals in the 10 months before and 12 months after the multimodal pain power plan launch. Women with prior substance use disorder or complicated deliveries were excluded and we stratified analyses into women who delivered vaginally compared with by cesarean. Opioid use was converted to morphine milligram equivalent (MME). Women rated pain control in 24-hour blocks using individually ascertained cutoffs. A multivariable regression analysis was performed, and adjusted odds ratios are reported. RESULTS: We compared the 6,892 women who delivered 10 months before the pain power plan launch to the 7,527 who delivered in the 12 months after the launch. The mean cohort age was 29.6±6.0 years; the majority (75%) were white. Risk of opioid use decreased by 26% among women who delivered vaginally (risk ratio [RR] 0.74; 95% CI [0.68, 0.81]) and 18% among women who delivered by cesarean (RR 0.82; 95% CI [0.72, 0.92]). Among women who received opioids, mean MME use decreased 21% (RR 0.79; 95% CI [0.70, 0.88]) and 54% (RR 0.46; 95% CI [0.35, 0.61]) in the vaginal and cesarean delivery groups, respectively. Fewer women reported acceptable pain levels, with decreases of 82-69% (P<.01) and 82-74% (P<.01) in the vaginal and cesarean delivery groups, respectively. Within the postlaunch cesarean delivery group, women also reported that they were less likely to have their pain well controlled on the Hospital Consumer Assessment of Healthcare Providers and Systems questionnaires (82% vs 62%, P <.01). CONCLUSION: A standardized multimodal pain power plan reduced opioid use among a large cohort of women admitted to labor and delivery in Central Texas. Despite meeting functional goals, some women reported increased pain during their hospital stay.

The Therapeutic Activity Goal for Acute Postoperative Pain Management.

Acute pain intensity has conventionally been assessed with a patient self-reported, unidimensional pain scale. This approach can inadvertently underestimate analgesia and result in large cumulative opioid doses and greater dose-dependent side effects and complications. We have thus created the Therapeutic Activity Goal (TAG) as an alternate, more comprehensive way to assess acute postoperative pain, and even more so, to define and determine adequate postoperative analgesia. The TAG comprises the level of acceptable pain intensity, the level and types of desired activities, and accomplishing other patient-centered functional goals. The TAG evolves throughout the patient's hospitalization to promote timely discharge.

Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran).

STUDY DESIGN: The authors present a case report of a 72-year-old man who presented with back pain and lower extremity weakness after a fall from his roof. OBJECTIVE: Use of dabigatran (Pradaxa), a new oral anticoagulant, is rapidly increasing. Spine specialists should aware of this medication's place for the management of patients with spine pathology. In particular, we intend to report on the emergent treatment of a patient with spinal trauma and epidural hematoma with cord compression. SUMMARY OF BACKGROUND DATA: Dabigatran (Pradaxa) is approved by the Food and Drug Administration to decrease stroke risk in patients with atrial fibrillation. Unlike warfarin, dabigatran does not require international normalized ratio monitoring. On the contrary, it is difficult to reverse in patients requiring emergent surgical intervention. METHODS.: This is a retrospective review of a patient treated at our institution. RESULTS: The patient presented with burst fractures at the T7 and T12 levels. Cord compression was noted at both levels, and was worse at T12. Canal stenosis resulted from both retropulsed bone and epidural hematoma. The patient exhibited bilateral lower extremity numbness and weakness, ASIA C. The patient was taken urgently to the operating room for cord decompression and planned operative stabilization. The treating team used a number of recommended "reversal" agents with little effect on the severe intraoperative hemorrhage. Failure to control the bleeding required interruption of the procedure after the canal decompression. The patient was taken back to the operating room 7 days later for an instrumented posterior spinal fusion. CONCLUSION: As dabigatran (Pradaxa) has recently been approved by the Food and Drug Administration, many spine specialists are not familiar with this agent. Many of the reversal agents (e.g., vitamin K and protamine), useful for other classes of anticoagulants, have no impact on Pradaxa. Similarly, prothrombin time and partial thromboplastin times have limited utility in estimating the patient's true clotting status. The purpose of this case report is to alert spine specialists to this drug and its implications on spine care. The drug's pharmacokinetics, clinical assessment of clotting status, and reversal options are discussed.

Sutureless avascular meniscal repair with a photoactive naphthalimide compound: a preliminary animal study.

PURPOSE: The purpose of this study was to evaluate the ability of 2 new photoactive naphthalimide compounds to repair a lesion in the avascular zone of the meniscus. TYPE OF STUDY: In vivo animal study. METHODS: Ten Barbados sheep were used as the animal model. Under anesthesia, the left knee joint was opened and 2 identical lesions were produced in the avascular zone of the medial meniscus. The posterior horn lesion was left alone and used as the control and the lesion in the anterior horn was repaired using the photoactive laser technique. The photoactive laser technique involved placing small amounts of a naphthalimide compound into the lesion and then irradiating the site with a laser (457 nm and 1.8 W/cm2) for 6 minutes. Two different versions of the naphthalimide compound were produced and divided between the 10 animals. The joint was then flushed with normal saline and closed in layers with resorbable sutures. Four animals were euthanized at the end of 1 month and 6 animals were euthanized at the end of 3 months. After death, the medial meniscus was exposed, dissected free, and then placed in 10% buffered formalin for histologic preparation and staining. RESULTS: At 1 month, the control lesions grossly showed no repair and the photochemically repaired lesions appeared to be bonded. The photochemically repaired lesions showed some bridging by an eosinophilic amorphous-appearing substance. The previous cleft within the fibrocartilaginous structure had disappeared, and early formation of connective tissue fibers was identified. However, some reduction in cellularity was seen in these tissue sections. At 3 months, again the control lesions did not show any repair response, while the photochemically repaired lesions showed results similar to the animals at 1 month, but with a less consistent pattern of tissue bonding and remodeling. The reduced tissue cellularity was still noted. There was no discernible difference between the naphthalimide compounds. CONCLUSIONS: These preliminary results demonstrate the potential usefulness of this photochemical bonding for the treatment of avascular meniscal lesions. Additional research will be necessary to fully understand the mechanism of this repair and optimize its use before any human trials. CLINICAL RELEVANCE: This is a preliminary animal study investigating the short-term in vivo effects of a novel photochemical compound for the repair of meniscal lesions. This repair may someday be valuable in the repair of avascular meniscal lesions.

The results of arthroscopic lavage and debridement of osteoarthritic knees based on the severity of degeneration: a 4- to 6-year symptomatic follow-up.

PURPOSE: A clinically and arthroscopically oriented staging system based on the severity of the degenerative process has been used in the assessment of the results of arthroscopic lavage and debridement of osteoarthritic (OA) knees. TYPE OF STUDY: Retrospective case series. METHODS: For eighteen months, commencing January 1995, every case of previously untreated OA referred for definitive treatment was clinically classified into 1 of 4 stages of increasing degeneration. Excluded were patients who were treated nonoperatively, by replacement arthroplasty or marrow stimulation techniques. A group of 121 cases treated by arthroscopic lavage and debridement were available for review with a 4 to 6 year follow-up. RESULTS: Arthroscopic lavage and debridement carried out in the earlier stages of the degenerative process resulted in significant relief of symptoms for reasonably long periods of time. The more advanced stages of degeneration commonly experienced some temporary relief from arthroscopic lavage and debridement, but the amount of improvement was unpredictable. CONCLUSIONS: The surgeon's armamentarium for the treatment of degenerative arthritis unresponsive to conservative treatment methods should involve minimal interventional arthroscopy at an earlier, rather than a later stage in the disease process. It is recommended that the arthroscopist be conservative in the surgical debridement, removing only the fibrillated and scaling fragments of articular cartilage.